Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.

Borrero-Palacios, ACebrián, AGómez Del Pulgar, M TGarcía-Carbonero, RGarcia-Alfonso, PAranda, EElez, ELópez-López, RCervantes, AValladares, MNadal, CViéitez, J MGuillén-Ponce, CRodríguez, JHernández, IGarcía, J LVega-Bravo, RPuime-Otin, AMartínez-Useros, JDel Puerto-Nevado, LRincón, RRodríguez-Remírez, MRojo, FGarcía-Foncillas, J2023-01-252023-01-252019-05-17http://hdl.handle.net/10668/13974A correction to this article has been published and is linked from the HTML and PDF versions of this paper. The error has been fixed in the paper.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer.research article31097738open access10.1038/s41598-019-43809-z2045-2322PMC6522500https://www.nature.com/articles/s41598-019-43809-z.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522500/pdf